vs
Organogenesis Holdings Inc.（ORGO）与STEM, INC.（STEM）财务数据对比。点击上方公司名可切换其他公司
STEM, INC.的季度营收约是Organogenesis Holdings Inc.的1.3倍（$47.1M vs $37.2M），STEM, INC.同比增速更快（-15.6% vs -57.1%），过去两年STEM, INC.的营收复合增速更高（36.1% vs -46.5%）
Organogenesis Holdings Inc.是一家领先的再生医学企业，专注于开发、生产用于伤口护理、外科修复、运动医学和皮肤病领域的先进治疗产品，主要服务美国及部分国际市场的医疗机构与患者，提供经临床验证的医疗解决方案。
该公司是一家公开上市的生物制药企业，总部位于加利福尼亚州纽瓦克，专注研发纯化人类神经干细胞，旨在治疗中枢神经系统疾病与瘫痪，其所研发的神经干细胞可分化为中枢神经系统的神经元、星形胶质细胞与少突胶质细胞这三大主要细胞类型。
ORGO vs STEM — 直观对比
营收规模更大
STEM
是对方的1.3倍
$37.2M
营收增速更快
STEM
高出41.5%
-57.1%
两年增速更快
STEM
近两年复合增速
-46.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.2M | $47.1M |
| 净利润 | — | $-16.0M |
| 毛利率 | 30.8% | 48.9% |
| 营业利润率 | -185.1% | -17.7% |
| 净利率 | — | -33.9% |
| 营收同比 | -57.1% | -15.6% |
| 净利润同比 | — | 68.8% |
| 每股收益（稀释后） | — | $-4.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORGOSTEM
| Q1 26 | $37.2M | — | ||
| Q4 25 | $225.6M | $47.1M | ||
| Q3 25 | $150.9M | $38.2M | ||
| Q2 25 | $101.0M | $38.4M | ||
| Q1 25 | $86.7M | $32.5M | ||
| Q4 24 | $126.7M | $55.8M | ||
| Q3 24 | $115.2M | $29.3M | ||
| Q2 24 | $130.2M | $34.0M |
净利润ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-16.0M | ||
| Q3 25 | $21.6M | $-23.8M | ||
| Q2 25 | $-9.4M | $202.5M | ||
| Q1 25 | $-18.8M | $-25.0M | ||
| Q4 24 | $7.7M | $-51.1M | ||
| Q3 24 | $12.3M | $-148.3M | ||
| Q2 24 | $-17.0M | $-582.3M |
毛利率ORGOSTEM
| Q1 26 | 30.8% | — | ||
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | 72.6% | 32.4% | ||
| Q4 24 | 75.5% | -4.4% | ||
| Q3 24 | 76.7% | 21.2% | ||
| Q2 24 | 77.6% | 27.6% |
营业利润率ORGOSTEM
| Q1 26 | -185.1% | — | ||
| Q4 25 | 28.1% | -17.7% | ||
| Q3 25 | 13.7% | -33.6% | ||
| Q2 25 | -12.5% | -34.8% | ||
| Q1 25 | -30.9% | -65.0% | ||
| Q4 24 | 8.1% | -84.4% | ||
| Q3 24 | 5.4% | -493.2% | ||
| Q2 24 | -10.7% | -1705.5% |
净利率ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | -33.9% | ||
| Q3 25 | 14.3% | -62.2% | ||
| Q2 25 | -9.3% | 527.8% | ||
| Q1 25 | -21.7% | -76.9% | ||
| Q4 24 | 6.1% | -91.6% | ||
| Q3 24 | 10.7% | -506.3% | ||
| Q2 24 | -13.1% | -1712.6% |
每股收益（稀释后）ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | $0.31 | $-4.40 | ||
| Q3 25 | $0.11 | $-2.84 | ||
| Q2 25 | $-0.10 | $-1.79 | ||
| Q1 25 | $-0.17 | $-0.15 | ||
| Q4 24 | $0.05 | $-15.29 | ||
| Q3 24 | $0.09 | $-18.24 | ||
| Q2 24 | $-0.13 | $-71.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $91.4M | $48.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $-249.4M |
| 总资产 | $520.0M | $308.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ORGOSTEM
| Q1 26 | $91.4M | — | ||
| Q4 25 | $93.7M | $48.9M | ||
| Q3 25 | $63.7M | $43.1M | ||
| Q2 25 | $73.1M | $40.8M | ||
| Q1 25 | $110.0M | $58.6M | ||
| Q4 24 | $135.6M | $56.3M | ||
| Q3 24 | $94.3M | $75.4M | ||
| Q2 24 | $89.9M | $89.6M |
总债务ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $62.3M | — | ||
| Q2 24 | $63.8M | — |
股东权益ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | $300.1M | $-249.4M | ||
| Q3 25 | $255.1M | $-235.7M | ||
| Q2 25 | $233.2M | $-214.1M | ||
| Q1 25 | $242.9M | $-417.5M | ||
| Q4 24 | $262.9M | $-398.4M | ||
| Q3 24 | $278.5M | $-344.1M | ||
| Q2 24 | $263.5M | $-203.2M |
总资产ORGOSTEM
| Q1 26 | $520.0M | — | ||
| Q4 25 | $598.7M | $308.9M | ||
| Q3 25 | $509.8M | $362.6M | ||
| Q2 25 | $461.1M | $379.2M | ||
| Q1 25 | $467.4M | $405.1M | ||
| Q4 24 | $497.9M | $437.4M | ||
| Q3 24 | $446.3M | $537.8M | ||
| Q2 24 | $443.2M | $691.5M |
负债/权益比ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.22× | — | ||
| Q2 24 | 0.24× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $8.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | $39.4M | $8.2M | ||
| Q3 25 | $3.1M | $11.4M | ||
| Q2 25 | $-32.9M | $-21.3M | ||
| Q1 25 | $-19.9M | $8.5M | ||
| Q4 24 | $10.9M | $-14.7M | ||
| Q3 24 | $8.7M | $-9.4M | ||
| Q2 24 | $4.7M | $-11.9M |
自由现金流ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | $34.8M | — | ||
| Q3 25 | $844.0K | — | ||
| Q2 25 | $-36.5M | — | ||
| Q1 25 | $-23.6M | — | ||
| Q4 24 | $7.6M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $2.9M | — |
自由现金流率ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | 15.4% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -36.1% | — | ||
| Q1 25 | -27.2% | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 5.3% | — | ||
| Q2 24 | 2.2% | — |
资本支出强度ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 1.4% | — |
现金转化率ORGOSTEM
| Q1 26 | — | — | ||
| Q4 25 | 0.90× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 0.71× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
